Roche enters deal to use PureTech's exosome platform for oral administration of antisense oligonucleotides

Roche entered a deal potentially worth more than $1 billion to use PureTech Health's milk-derived exosome platform technology for the oral administration of its antisense oligonucleotide platform, the latter company announced Friday. Under the agreement, Roche will make payments of $36 million to PureTech covering upfront fees, research support and early preclinical milestones, with the latter eligible to receive further development and sales milestone payments, as well as royalties for an undisclosed number of products.

PureTech noted that its milk exosome-based technology is designed to facilitate the oral administration of complex payloads, such as nucleic acids, peptides and small molecules. PureTech said that the "exosomes are believed to traffic via lymphatic circulation and could potentially enable the targeting of immune cells in novel ways."

Commenting on the deal, PureTech CEO Daphne Zohar remarked "the expertise and resources that Roche is bringing to the collaboration will help us to potentially address one of the biggest challenges in oligonucleotide-based therapeutic development: oral administration of nucleic acids."

To read more Top Story articles, click here.